Vimarsana
Biggest News Aggregation in the World

Biocon Generics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biocon Generics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biocon Generics Inc Today - Breaking & Trending Today

Trade setup for Monday: 15 things to know before opening bell - Vimarsana News

Trade setup for Monday: 15 things to know before opening bell

A short build-up was seen in 67 stocks including Canara Bank, Oracle Financial Services Software, India Cements, Metropolis Healthcare, and IndiaMART InterMESH.

Stocks in news: IDFC First Bank, Kotak Mahindra Bank, IDBI Bank, Shaily Engineering, RVNL - Vimarsana News

Stocks in news: IDFC First Bank, Kotak Mahindra Bank, IDBI Bank, Shaily Engineering, RVNL

GMR Smart Electricity Distribution, a step down subsidiary of GMR Power and Urban Infra, has received a letter of award (LOA) from Purvanchal Vidyut Vitran Nigam to implement a smart metering project in Purvanchal.

Stocks to Watch: Infosys, RIL, ONGC, Tata Motors, Coal India, IDFC First, and Others - Vimarsana News

Stocks to Watch: Infosys, RIL, ONGC, Tata Motors, Coal India, IDFC First, and Others

Stocks to watch: Shares of firms like Infosys, RIL, ONGC, Tata Motors, Coal India, IDFC First, and others will be in focus on Monday's trade.

Source: news18.com
Trade setup for Monday: Top 15 things to know before the opening bell - Vimarsana News

Trade setup for Monday: Top 15 things to know before the opening bell

For the Nifty, the short term outlook looks positive, say analysts. The index is likely to face a hurdle at 19,500 on the higher side and then at 19,650. On the lower side, support is at 19,300-19,250

Biocon acquires Eywa Pharma's New Jersey facility for $7.7 million - Vimarsana News

Biocon acquires Eywa Pharma's New Jersey facility for $7.7 million

The biotechnology giant stated in an exchange filing that the facility in New Jersey's Cranbury in the US has the potential for further expanding its capacity up to two billion tablets or capsules per year